levosert
gedeon richter plc., maďarsko - vnútromaternicové teliesko s progestínom - 17 - anticoncipientia
eginilla
egis pharmaceuticals plc, maďarsko - ulipristal - 17 - anticoncipientia
mirena
bayer, spol. s r.o., slovensko - vnútromaternicové teliesko s progestínom - 17 - anticoncipientia
tri-regol 21+7
gedeon richter plc. - levonorgestrel a etinylestradiol - 17 - anticoncipientia
drovelis
gedeon richter plc. - drospirenone, estetrol monohydrate - contraceptives, oral - pohlavné hormóny a modulátory z genitálny systém, - oral contraceptive.
lydisilka
estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - pohlavné hormóny a modulátory z genitálny systém, - orálna antikoncepcia. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.
perlinring
actavis group ptc ehf., island - vaginálne krúžky s progestínom a estrogénom - 17 - anticoncipientia
maviret
abbvie deutschland gmbh co. kg - glecaprevir, pibrentasvir - hepatitída c, chronická - antivirotiká na systémové použitie - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and children aged 3 years and older. maviret coated granules is indicated for the treatment of chronic hepatitis c virus (hcv) infection in children 3 years and older.
lyxumia
sanofi winthrop industrie - lixisenatidu - diabetes mellitus, typ 2 - drugs used in diabetes, glucagon-like peptide-1 (glp-1) analogues - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
suliqua
sanofi winthrop industrie - inzulín glargine, lixisenatide - diabetes mellitus, typ 2 - lieky používané pri cukrovke - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.